Matthew M Kalscheur1, Ravi Vaidyanathan1, Kate M Orland2, Sara Abozeid1, Nicholas Fabry1, Kathleen R Maginot2, Craig T January3, Jonathan C Makielski1, Lee L Eckhardt4. 1. Cellular and Molecular Arrhythmia Research Program, University of Wisconsin-Madison, Wisonsin. 2. University of Wisconsin-Madison Inherited Arrhythmia Clinic, Division of Cardiovascular Medicine, Department of Medicine, University of Wisconsin-Madison, Wisconsin. 3. Cellular and Molecular Arrhythmia Research Program, University of Wisconsin-Madison, Wisonsin; University of Wisconsin-Madison Inherited Arrhythmia Clinic, Division of Cardiovascular Medicine, Department of Medicine, University of Wisconsin-Madison, Wisconsin. 4. Cellular and Molecular Arrhythmia Research Program, University of Wisconsin-Madison, Wisonsin; University of Wisconsin-Madison Inherited Arrhythmia Clinic, Division of Cardiovascular Medicine, Department of Medicine, University of Wisconsin-Madison, Wisconsin. Electronic address: lle@medicine.wisc.edu.
Abstract
BACKGROUND: KCNJ2 mutations are associated with a variety of inherited arrhythmia syndromes including catecholaminergic polymorphic ventricular tachycardia 3. OBJECTIVE: To characterize the detailed cellular mechanisms of the clinically recognized KCNJ2 mutation R67Q. METHODS: Kir2.1 current density was measured from COS-1 cells transiently transfected with wild-type human Kir-2.1 (WT-Kir2.1) and/or a heterozygous missense mutation in KCNJ2 (R67Q-Kir2.1) by using the whole-cell voltage clamp technique. Catecholamine activity was simulated with protein kinase A-stimulating cocktail exposure. Phosphorylation-deficient mutants, S425N-Kir2.1 and S425N-Kir2.1/R67Q-S425N-Kir2.1, were used in a separate set of experiments. HA- or Myc-Tag-WT-Kir2.1 and HA-Tag-R67Q-Kir2.1 were used for confocal imaging. RESULTS: A 33-year-old woman presented with a catecholaminergic polymorphic ventricular tachycardia-like clinical phenotype and was found to have KCNJ2 missense mutation R67Q. Treatment with nadolol and flecainide resulted in the complete suppression of arrhythmias and symptom resolution. Under baseline conditions, R67Q-Kir2.1 expressed alone did not produce inward rectifier current while cells coexpressing WT-Kir2.1 and R67Q-Kir2.1 demonstrated the rectification index (RI) similar to that of WT-Kir2.1. After PKA stimulation, R67Q-Kir2.1/WT-Kir2.1 failed to increase peak outward current density; WT-Kir2.1 increased by 46% (n = 5), while R67Q-Kir2.1/WT-Kir2.1 decreased by 6% (n = 6) (P = .002). Rectification properties in R67Q-Kir2.1/WT-Kir2.1 demonstrated sensitivity to calcium with a decreased RI in the high-calcium pipette solution (RI 20.3% ± 4.1%) than in the low-calcium pipette solution (RI 36.5% ± 5.7%) (P < .05). Immunostaining of WT-Kir2.1 and R67Q-Kir2.1 individually and together showed a normal membrane expression pattern and colocalization by using the Pearson correlation coefficient. CONCLUSIONS: R67Q-Kir2.1 is associated with an adrenergic-dependent clinical and cellular phenotype with rectification abnormality enhanced by increased calcium. These findings are a significant advancement of our knowledge and understanding of the phenotype-genotype relationship of arrhythmia syndromes related to KCNJ2 mutations.
BACKGROUND:KCNJ2 mutations are associated with a variety of inherited arrhythmia syndromes including catecholaminergic polymorphic ventricular tachycardia 3. OBJECTIVE: To characterize the detailed cellular mechanisms of the clinically recognized KCNJ2 mutation R67Q. METHODS:Kir2.1 current density was measured from COS-1 cells transiently transfected with wild-type humanKir-2.1 (WT-Kir2.1) and/or a heterozygous missense mutation in KCNJ2 (R67Q-Kir2.1) by using the whole-cell voltage clamp technique. Catecholamine activity was simulated with protein kinase A-stimulating cocktail exposure. Phosphorylation-deficient mutants, S425N-Kir2.1 and S425N-Kir2.1/R67Q-S425N-Kir2.1, were used in a separate set of experiments. HA- or Myc-Tag-WT-Kir2.1 and HA-Tag-R67Q-Kir2.1 were used for confocal imaging. RESULTS: A 33-year-old woman presented with a catecholaminergic polymorphic ventricular tachycardia-like clinical phenotype and was found to have KCNJ2 missense mutation R67Q. Treatment with nadolol and flecainide resulted in the complete suppression of arrhythmias and symptom resolution. Under baseline conditions, R67Q-Kir2.1 expressed alone did not produce inward rectifier current while cells coexpressing WT-Kir2.1 and R67Q-Kir2.1 demonstrated the rectification index (RI) similar to that of WT-Kir2.1. After PKA stimulation, R67Q-Kir2.1/WT-Kir2.1 failed to increase peak outward current density; WT-Kir2.1 increased by 46% (n = 5), while R67Q-Kir2.1/WT-Kir2.1 decreased by 6% (n = 6) (P = .002). Rectification properties in R67Q-Kir2.1/WT-Kir2.1 demonstrated sensitivity to calcium with a decreased RI in the high-calcium pipette solution (RI 20.3% ± 4.1%) than in the low-calcium pipette solution (RI 36.5% ± 5.7%) (P < .05). Immunostaining of WT-Kir2.1 and R67Q-Kir2.1 individually and together showed a normal membrane expression pattern and colocalization by using the Pearson correlation coefficient. CONCLUSIONS:R67Q-Kir2.1 is associated with an adrenergic-dependent clinical and cellular phenotype with rectification abnormality enhanced by increased calcium. These findings are a significant advancement of our knowledge and understanding of the phenotype-genotype relationship of arrhythmia syndromes related to KCNJ2 mutations.
Authors: Kimmo Kontula; Päivi J Laitinen; Annukka Lehtonen; Lauri Toivonen; Matti Viitasalo; Heikki Swan Journal: Cardiovasc Res Date: 2005-08-15 Impact factor: 10.787
Authors: S G Priori; C Napolitano; N Tiso; M Memmi; G Vignati; R Bloise; V Sorrentino; G A Danieli Journal: Circulation Date: 2001-01-16 Impact factor: 29.690
Authors: Terrence U H Chun; Michael R Epstein; Macdonald Dick; Gregor Andelfinger; Leomar Ballester; Carlos G Vanoye; Alfred L George; D Woodrow Benson Journal: Heart Rhythm Date: 2004-07 Impact factor: 6.343
Authors: Li Zhang; D Woodrow Benson; Martin Tristani-Firouzi; Louis J Ptacek; Rabi Tawil; Peter J Schwartz; Alfred L George; Minoru Horie; Gregor Andelfinger; Gregory L Snow; Ying-Hui Fu; Michael J Ackerman; G Michael Vincent Journal: Circulation Date: 2005-05-23 Impact factor: 29.690
Authors: Gregor Andelfinger; Andrew R Tapper; Richard C Welch; Carlos G Vanoye; Alfred L George; D Woodrow Benson Journal: Am J Hum Genet Date: 2002-07-29 Impact factor: 11.025
Authors: Silvia G Priori; Sandeep V Pandit; Ilaria Rivolta; Omer Berenfeld; Elena Ronchetti; Amit Dhamoon; Carlo Napolitano; Justus Anumonwo; Marina Raffaele di Barletta; Smitha Gudapakkam; Giuliano Bosi; Marco Stramba-Badiale; José Jalife Journal: Circ Res Date: 2005-03-10 Impact factor: 17.367
Authors: Ravinea Manotheepan; Tore K Danielsen; Mani Sadredini; Mark E Anderson; Cathrine R Carlson; Stephan E Lehnart; Ivar Sjaastad; Mathis K Stokke Journal: Cardiovasc Res Date: 2016-05-08 Impact factor: 10.787
Authors: Louise Reilly; Francisco J Alvarado; Di Lang; Sara Abozeid; Hannah Van Ert; Cordell Spellman; Jarrett Warden; Jonathan C Makielski; Alexey V Glukhov; Lee L Eckhardt Journal: Circ Arrhythm Electrophysiol Date: 2020-08-04
Authors: Hanora A Van Ert; Elise C McCune; Kate M Orland; Kathleen R Maginot; Nicholas H Von Bergen; Craig T January; Lee L Eckhardt Journal: HeartRhythm Case Rep Date: 2016-12-09
Authors: Thomas M Roston; Taylor Cunningham; Anna Lehman; Zachary W Laksman; Andrew D Krahn; Shubhayan Sanatani Journal: Clin Med Insights Cardiol Date: 2017-03-16
Authors: Estefanía Martínez-Barrios; Sergi Cesar; José Cruzalegui; Clara Hernandez; Elena Arbelo; Victoria Fiol; Josep Brugada; Ramon Brugada; Oscar Campuzano; Georgia Sarquella-Brugada Journal: Biomedicines Date: 2022-01-05